Volume Spike Investor

Myriad Genetics Inc. (NASDAQ: MYGN) is rising sharply this morning after earnings, or technically after it reported a smaller than forecast drop in profit. So far we have seen one upgrade: Canaccord raised its rating to BUY from HOLD.  At 8:55 AM EST we have seen some 156,000 shares trade hands and the stock is [...]

Myriad Genetics Inc. (NASDAQ: MYGN) announced this morning that the company beat earnings significantly with $0.30 EPS and $73.7 million in revenues.  Thomson Reuters (First Call) estimates were $0.14 EPS and $70.4 million in revenues.
The biotech company also said it remains in strong financial condition with $443 million in cash and equivalents.  Its market cap [...]

Myriad Genetics (NASDAQ: MYGN) is seeing strong selling pressure in the pre-market hours this Monday. The culprit is that plans to discontinue the development of Alzheimer treatment Flurizan after its late-stage trial failed to meet endpoints.
The stock has recovered off of its lows as shares had briefly been down more than 10%.  Shares are currently [...]